Alembic Pharmaceuticals Limited has issued a postal ballot notice dated 27th February, 2026, seeking shareholder approval for two significant corporate governance matters through remote e-voting.

Key Resolutions for Shareholder Approval

The pharmaceutical company has proposed two resolutions for member consideration. The first involves the appointment of Mr. Rajkumar Baheti (DIN: 00332079) as Non-Executive Non-Independent Director, while the second seeks approval for professional fee payments to the same individual.

Leadership Transition Details

Mr. Rajkumar Baheti will complete his tenure as Executive Director on 31st March, 2026. The Board of Directors, based on the Nomination and Remuneration Committee's recommendation, approved his transition to Non-Executive Non-Independent Director role effective 1st April, 2026. This transition aims to ensure continuity at the Board level during the management succession process.

The proposed director brings over 45 years of professional experience in finance, taxation, regulatory compliance, and corporate governance. He is a fellow member of both the Institute of Chartered Accountants of India and the Institute of Company Secretaries of India, having been associated with the company as a Director since its incorporation.

Professional Services Engagement

The second resolution addresses the approval of professional fees for Mr. Baheti's consultancy services in his individual capacity. The professional engagement covers strategic inputs to the Board and senior management, advisory support for legacy matters, and transitional support during management succession.

Voting Schedule and Process

The company has established a comprehensive e-voting timeline for shareholder participation. Members whose names appear on the Register of Members as of 20th February, 2026 (Cut-Off Date) are eligible to participate in the voting process.

Regulatory Compliance and Governance

The postal ballot notice complies with Section 110 read with Section 108 of the Companies Act, 2013, and various SEBI regulations. The professional engagement with Mr. Baheti constitutes a related party transaction under Section 188(1)(f) of the Companies Act, requiring special resolution approval as the fees exceed prescribed monetary limits.

The Audit Committee has reviewed and approved the proposed professional engagement in accordance with the company's Policy on Related Party Transactions. The transaction does not constitute a material related party transaction under SEBI Listing Regulations.

Director Profile and Remuneration

Mr. Rajkumar Baheti, aged 66 years, has drawn remuneration of Rs. 5.35 crores during the financial year 2025-26 up to the notice date. He has attended four Board meetings during the current financial year and holds no shares in the company. Upon appointment as Non-Executive Director, he will be liable to retire by rotation and will continue serving on the Stakeholder Relationship Committee, Risk Management Committee, and Administrative Sub-Committee.

Alembic Pharmaceuticals has received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Lamotrigine Orally Disintegrating Tablets USP in four dosage strengths. The company announced this regulatory milestone, which expands its portfolio in the specialized neurological therapeutics segment.

Product Specifications and Approval Details

The approved ANDA covers Lamotrigine Orally Disintegrating Tablets USP in 25 mg, 50 mg, 100 mg and 200 mg strengths. The approved product is therapeutically equivalent to the reference listed drug product (RLD), Lamictal ODT Orally Disintegrating Tablets of GlaxoSmithKline LLC.

Therapeutic Applications

Lamotrigine is indicated as adjunctive therapy in patients aged 2 years and older for partial-onset seizures, primary generalized tonic-clonic (PGTC) seizures, and generalized seizures of Lennox-Gastaut syndrome. The medication is also approved for conversion to monotherapy in adults aged 16 years and older with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug (AED).

Additionally, Lamotrigine is indicated for the maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy.

Market Opportunity and Strategic Impact

According to IQVIA data, Lamotrigine Orally Disintegrating Tablets USP have an estimated market size of $27.00 million for the twelve months ending December 2025. The orally disintegrating tablet format addresses specific patient needs, particularly for individuals with swallowing difficulties or those requiring discrete medication administration.

With this latest approval, Alembic Pharmaceuticals now holds a cumulative total of 235 ANDA approvals from the USFDA, comprising 216 final approvals and 19 tentative approvals. This achievement strengthens the company's position in the competitive US generics market and demonstrates its capability in developing complex pharmaceutical formulations for neurological and psychiatric treatments.